EU Commission approves Roche Susvimo for wet age-related macular degeneration
EU approval for Susvimo in wet AMD
- The European Commission has cleared Roche’s Susvimo (ranibizumab) for neovascular age-related macular degeneration in the EU.
- The approval enables use of the Contivue refillable eye implant, which is positioned as an alternative to regular anti-VEGF injections.
- Phase III Archway data showed vision outcomes matched monthly intravitreal ranibizumab, with dosing as few as two refills a year.
